Literature DB >> 20667468

Alternative ERK5 regulation by phosphorylation during the cell cycle.

Francisco A Iñesta-Vaquera1, David G Campbell, Cathy Tournier, Nestor Gómez, Jose M Lizcano, A Cuenda.   

Abstract

ERK5 is a member of the mitogen-activated protein kinase (MAPK) family that, after stimulation, is activated selectively by dual phosphorylation in the TEY motif by MAPK kinase 5 (MEK5). ERK5 plays an important role in regulating cell proliferation, survival, differentiation and stress response. Moreover, it is involved in G2/M progression and timely mitotic entry. ERK5 is phosphorylated during mitosis, but the molecular mechanism by which it is regulated during this phase is still unclear. Here we show that although ERK5 is phosphorylated in mitosis, this does not occur on the activation motif (TEY), but at its C-terminal half. We have identified five sites of ERK5 phosphorylation in mitosis, two of them unknown. Furthermore, we demonstrate that ERK5 phosphorylation in mitosis is not MEK5-dependent, but rather, cyclin-dependent kinase (CDK)-dependent. Using a mutagenesis approach, we analysed the importance of the phosphorylated residues in ERK5 function; our evidence show that phosphorylation in mitosis of the residues identified inhibits ERK5 activity and regulates ERK5 shuttling from cytoplasm to the nucleus. These results reveal a previously unreported form of ERK5 regulation by phosphorylation and establish a link between CDK and ERK5 pathways during mitosis, which could be crucial for the correct progression of the cell cycle.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20667468     DOI: 10.1016/j.cellsig.2010.07.010

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  22 in total

1.  Endothelial protective genes induced by statin are mimicked by ERK5 activation as triggered by a drug combination of FTI-277 and GGTI-298.

Authors:  Uyen B Chu; Tyler Duellman; Sara J Weaver; Yunting Tao; Jay Yang
Journal:  Biochim Biophys Acta       Date:  2015-03-28

2.  The platelet phenotype in patients with ST-segment elevation myocardial infarction is different from non-ST-segment elevation myocardial infarction.

Authors:  Rachel A Schmidt; Craig N Morrell; Frederick S Ling; Preya Simlote; Genaro Fernandez; David Q Rich; David Adler; Joe Gervase; Scott J Cameron
Journal:  Transl Res       Date:  2017-12-02       Impact factor: 7.012

3.  ERK5 kinase activity is dispensable for cellular immune response and proliferation.

Authors:  Emme C K Lin; Christopher M Amantea; Tyzoon K Nomanbhoy; Helge Weissig; Junichi Ishiyama; Yi Hu; Shyama Sidique; Bei Li; John W Kozarich; Jonathan S Rosenblum
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-27       Impact factor: 11.205

4.  Erk5 contributes to maintaining the balance of cellular nucleotide levels and erythropoiesis.

Authors:  Maria Angulo-Ibáñez; Xavier Rovira-Clavé; Alba Granados-Jaén; Bradley Downs; Yeong C Kim; San Ming Wang; Manuel Reina; Enric Espel
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).

Authors:  Xuening Wang; Elzbieta Gocek; Victoria Novik; Jonathan S Harrison; Michael Danilenko; George P Studzinski
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

6.  Targeting the BMK1 MAP kinase pathway in cancer therapy.

Authors:  Qingkai Yang; Jiing-Dwan Lee
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

7.  Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex.

Authors:  Tatiana Erazo; Ana Moreno; Gerard Ruiz-Babot; Arantza Rodríguez-Asiain; Nicholas A Morrice; Josep Espadamala; Jose R Bayascas; Nestor Gómez; Jose M Lizcano
Journal:  Mol Cell Biol       Date:  2013-02-19       Impact factor: 4.272

8.  ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma.

Authors:  Laura Arias-González; Inmaculada Moreno-Gimeno; Antonio Rubio del Campo; Leticia Serrano-Oviedo; María Llanos Valero; Azucena Esparís-Ogando; Miguel Ángel de la Cruz-Morcillo; Pedro Melgar-Rojas; Jesús García-Cano; Francisco José Cimas; María José Ruiz Hidalgo; Alfonso Prado; Juan Luis Callejas-Valera; Syong Hyun Nam-Cha; José Miguel Giménez-Bachs; Antonio S Salinas-Sánchez; Atanasio Pandiella; Luis del Peso; Ricardo Sánchez-Prieto
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

Review 9.  A walk-through MAPK structure and functionality with the 30-year-old yeast MAPK Slt2.

Authors:  Gema González-Rubio; Ángela Sellers-Moya; Humberto Martín; María Molina
Journal:  Int Microbiol       Date:  2021-05-15       Impact factor: 2.479

10.  Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer.

Authors:  I Ahmad; L B Singh; Z H Yang; G Kalna; J Fleming; G Fisher; C Cooper; J Cuzick; D M Berney; H Møller; P Scardino; H Y Leung
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.